Mynzepli (Aflibercept)

Aflibercept, the active ingredient in Mynzepli, is a VEGF inhibitor presented as a solution for intravitreal injection for intravitreal use. It treats neovascular (wet) age‑related macular degeneration, diabetic macular edema and macular edema secondary to retinal vein occlusion in adult patients.

GNH USA supplies Mynzepli as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mynzepli (aflibercept) is used in ocular conditions driven by vascular endothelial growth factor (VEGF)–mediated angiogenesis.

- Neovascular (wet) age‑related macular degeneration: reduces fluid accumulation and stabilizes or improves visual acuity. - Diabetic macular edema: decreases retinal swelling and helps maintain vision. - Macular edema secondary to retinal vein occlusion: limits edema and supports visual function.

Intravitreal administration of aflibercept may be associated with ocular and systemic adverse reactions.

Common Side Effects: - Ocular pain or discomfort at the injection site. - Conjunctival hemorrhage. - Transient increase in intra‑ocular pressure. - Mild anterior chamber inflammation.

Serious or Rare Side Effects: - Endophthalmitis (intra‑ocular infection). - Retinal detachment. - Arterial thromboembolic events (e.g., stroke, myocardial infarction). - Severe hypersensitivity or anaphylactic reaction.

Prior to injection, clinicians should assess ocular health and systemic risk factors.

- Screen for active ocular infection: postpone injection if conjunctivitis or endophthalmitis is present. - Monitor intra‑ocular pressure: check pressure immediately after the procedure. - Avoid in recent intra‑ocular surgery: wait the recommended interval before administering. - Use strict aseptic technique: ensure sterile environment and equipment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Aflibercept may interact with other systemic or ocular agents that affect vascular or coagulation pathways.

Major Interactions (Avoid): - Concurrent intra‑ocular anti‑VEGF therapy: risk of cumulative toxicity. - Systemic VEGF inhibitors (e.g., bevacizumab): may increase systemic adverse events. - Anticoagulants or antiplatelet agents: heightened risk of intra‑ocular hemorrhage.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may influence wound healing and infection risk. - Chemotherapeutic agents with vascular effects: monitor ocular status and systemic safety.